Hot Biotech Stocks To Watch Right Now

tags:ARQL,BIIB,ALNY,AMGN,

On Tuesday, our Under the Radar Movers�newsletter suggested small cap clinical-stage biotechnology stock Threshold Pharmaceuticals (NASDAQ: THLD) as a long trade:

��The chart below speaks for itself. After trying to work its way above a ceiling at $0.62 for the past several months, that finally happened today, in earnest. Better still, it's happened after a strong foundation was laid, and it started with the gradual building of momentum. That foundation means this breakout move is built to last for a while.��

��As you can see, at the very least there's a gap from September that needs to be filled. If you think there's been several 'accumulation' days along the way, you're not imagining that either. The bulls have tipped their hand a couple of times here.��

Our Under the Radar Movers�newsletter would have a more detailed discussion about small cap Threshold Pharmaceuticals�� technical chart along with a potential long trading strategy:

Hot Biotech Stocks To Watch Right Now: ArQule Inc.(ARQL)

Advisors' Opinion:

• [By Maxx Chatsko]

  Shares of development-stage biopharma ArQule (NASDAQ:ARQL) rose nearly 17% today after the company announced two appointments to its management team in two newly created positions. Dr. Marc Schegerin will serve as senior vice president, corporate strategy, communication, and finance. Dr. Shirish Hirani will serve as senior vice president, program management and product planning.�

• [By Joseph Griffin]

  ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.

  Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.

• [By Joseph Griffin]

  Shares of ArQule, Inc. (NASDAQ:ARQL) were down 5.4% during trading on Wednesday . The company traded as low as $4.71 and last traded at $4.73. Approximately 3,358,864 shares traded hands during trading, an increase of 289% from the average daily volume of 863,008 shares. The stock had previously closed at $5.00.

Hot Biotech Stocks To Watch Right Now: Biogen Idec Inc(BIIB)

Advisors' Opinion:

• [By Keith Speights]

  Three biotech stocks that achieved this feat this week are�Nightstar Therapeutics (NASDAQ:NITE),�Arbutus Biopharma (NASDAQ:ABUS), and�Biogen (NASDAQ:BIIB). What caused these stocks to soar, and are they smart picks to buy now? Here's what you need to know.

• [By Keith Speights]

  This has been a bad year for Biogen (NASDAQ:BIIB) so far -- the biotech's stock has dropped more than 10% since it began. But 2018 has been horrible for Acadia Pharmaceuticals (NASDAQ:ACAD), which has seen its share price plunge nearly 40%.

• [By Chris Lange]

  The S&P 500 stock posting the largest daily percentage loss ahead of the close Monday was Biogen Inc. (NASDAQ: BIIB) which traded down nearly 4% at $329.58. The stock��s 52-week range is $244.28 to $348.84. Volume was 1.2 million matching the daily average of 1.2 million shares.

• [By Brian Feroldi]

  Data source: Alkermes. GAAP = generally accepted accounting principles.

  What happened with Alkermes this quarter? Sales of Alkermes'�opioid- and alcohol-abuse prevention drug Vivitrol grew 7% to $62.7 million. Sales of the company's�schizophrenia drug�Aristada�rose 62% to $29.2 million. Manufacturing and royalty revenue related to�Johnson & Johnson's schizophrenia drugs jumped 15% to $68.8 million. Manufacturing and royalty revenue related to�Acorda Therapeutics' multiple sclerosis drug�fell�3% to $28.3 million. Research and development revenue earned as part of its collaboration with�Biogen (NASDAQ:BIIB) for BIIB098 -- which used to be called ALKS 8700 -- was $17.5 million.

  Looking beyond the financials, here's an overview of the key events from the period:

• [By Chris Lange]

  Short interest in Biogen Inc. (NASDAQ: BIIB) increased to 4.73 million shares from the previous 4.33 million. The stock recently traded at $291.92, within a 52-week range of $249.17 to $370.57.

• [By Steve Symington]

  But several individual stocks lagged the broader market. Read on to see why Cerner (NASDAQ:CERN), Biogen (NASDAQ:BIIB), and Alphabet (NASDAQ:GOOG)(NASDAQ:GOOGL)�slumped today.

Hot Biotech Stocks To Watch Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors' Opinion:

• [By Max Byerly]

  Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.06. The business had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $35.23 million. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.25) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.7 earnings per share for the current fiscal year.

• [By Logan Wallace]

  Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company.  However, Alnylam reported positive data from the ATLAS study in the first quarter which led to regulatory filings for its late-stage pipeline candidate patisiran and the FDA set an action date of Aug 11, 2018. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020.”

• [By Keith Speights]

  It's not exactly David vs. Goliath. However, Bellicum Pharmaceuticals (NASDAQ:BLCM) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are definitely in different leagues right now. Both are clinical-stage biotechs, but Bellicum's market cap is less than $350 million while Alnylam's market cap is close to $10 billion.

• [By Brian Orelli]

  Alnylam Pharmaceuticals (NASDAQ:ALNY) released first-quarter results last week, but all eyes were looking forward as the company waits for a potential approval of its hereditary TTR amyloidosis (ATTR) drug, patisiran.

Hot Biotech Stocks To Watch Right Now: Amgen Inc.(AMGN)

Advisors' Opinion:

• [By Brian Feroldi]

  The study in question�is called ADVANCE. This phase 3 trial was designed to demonstrate noninferiority of Spectrum's drug Rolontis when compared to Amgen's (NASDAQ:AMGN) megablockbuster drug Neulasta in patients with early-stage breast cancer.

• [By Todd Campbell]

  Neulasta has been one of Amgen's (NASDAQ:AMGN) crown jewels for years, but following FDA approval of Mylan's (NASDAQ:MYL) Neulasta biosimilar this week, Amgen could see Neulasta's revenue slow to a trickle. Is Mylan about to deliver a big blow to Amgen's market share? Read on to find out what's at stake for these companies and their investors.

• [By Zacks]

  The FDA also approved biosimilar Erelzi in 2016. However, the launch is pending in the United States due to an ongoing litigation with Amgen (NASDAQ: AMGN).

• [By Keith Speights]

  It's not too hard to find biotech stocks that are bargains right now. Two of the most attractively priced biotech stocks on the market are Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD). Both stocks also provide nice dividend yields for income-seeking investors.

How Funko Is Riding the Fortnite Wave

Funko Inc. (NASDAQ: FNKO) shares saw a solid gain on Wednesday after the company announced that it had a new partnership with Epic Games to create a range of Fortnite toys and collectibles.

The new Fortnite branded collection will feature more than ten different product lines, including Funko��s iconic Pop! figures, 5 Star figures, Pint Size Heroes, Vynl, keychains, POP! apparel and more.

Launching holiday 2018, the collection will be available for purchase at a broad array of retailers worldwide.

Fortnite is the action building game from Epic Games that lets you drop into a massive 100-player PVP Battle Royale. It has become one of the most wildly popular games in 2018.

Brian Mariotti, CEO of Funko, commented:

We are thrilled to collaborate and partner with Epic Games to create the inaugural Fortnite product collection and to bring these characters to life for the first time. This collection will be a true celebration of Fortnite��s incredible popularity and cultural significance, and we believe our Funko Fortnite collectibles will strongly resonate with fans of the game. We look forward to expanding this collection and combining our leading product capabilities with our strong retail platform. Ultimately our goal is to create a powerful merchandise strategy for the Fortnite brand, as well as bring these amazing collectibles to fans around the world.

Shares of Funko were last seen up about 13% at $17.55, with a consensus analyst price target of $13.63 and a 52-week trading range of $5.81 to $18.42.

24/7 Wall St.
5 Mega-Cap S&P 500 Stocks to Buy Now for the Rest of 2018

EVO Payments (EVOP) Sets New 1-Year High at $23.76

EVO Payments Inc (NASDAQ:EVOP) shares reached a new 52-week high during trading on Thursday . The stock traded as high as $23.76 and last traded at $22.93, with a volume of 3028 shares changing hands. The stock had previously closed at $22.84.

Several research firms have commented on EVOP. Citigroup began coverage on shares of EVO Payments in a report on Monday, June 18th. They set a “neutral” rating and a $23.00 price objective for the company. SunTrust Banks began coverage on shares of EVO Payments in a report on Monday, June 18th. They set a “buy” rating and a $27.00 price objective for the company. Cowen began coverage on shares of EVO Payments in a report on Monday, June 18th. They set a “market perform” rating and a $22.00 price objective for the company. JPMorgan Chase & Co. began coverage on shares of EVO Payments in a report on Monday, June 18th. They set an “overweight” rating and a $27.00 price objective for the company. Finally, William Blair began coverage on shares of EVO Payments in a report on Monday, June 18th. They set an “outperform” rating for the company. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. EVO Payments has an average rating of “Hold” and an average price target of $23.86.

Get EVO Payments alerts:

The company has a debt-to-equity ratio of -4.29, a current ratio of 1.02 and a quick ratio of 1.01.

In related news, Director Gregory S. Pope acquired 50,000 shares of the company’s stock in a transaction on Tuesday, May 22nd. The stock was acquired at an average price of $16.00 per share, with a total value of $800,000.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

EVO Payments Company Profile

EVO Payments, Inc operates as an integrated merchant acquirer and payment processor servicing approximately 525,000 merchants. The company processes approximately 900 million transactions in North America and approximately 1.7 billion transactions in Europe. Its payment and commerce solutions consist of gateway solutions, online fraud prevention and management reporting, online hosted payments page capabilities, security tokenization, and encryption solutions at the point-of-sale and online; dynamic currency conversion; loyalty offers; and other ancillary solutions.

Featured Article: Price to Earnings Ratio (PE), For Valuing Stocks

Dollar gains as consumer inflation data expected to back interest-rate view

The U.S. dollar advanced modestly against major rivals in subdued Thursday action as U.S. inflation data and a downgrade for a European growth forecast took precedence over the trade-row concerns that had dominated recent forex dealings.

The ICE Dollar Index DXY, -0.02% which gauges the U.S. unit against six currencies and favors the euro, climbed by 0.2% to 94.91. A broader measure of the dollar against 16 currencies, the WSJ Dollar Index BUXX, -0.03% rose 0.1% to 88.51.

��Investors have been piling in on the dollar because of higher interest rates in the U.S. and expectations that monetary conditions will tighten further in the coming months,�� said Fawad Razaqzada, currency analyst with Forex.com.

Consumer-level inflation data for June are due at 8:30 a.m. Eastern Time. A strong reading could further strengthen speculation the Fed will raise rates two more times this year, bringing the total to four hikes in 2018. Economists polled by MarketWatch expect consumer prices to have risen 0.2% month-on-month in June.

��With U.S. employment already near its potential, unemployment low and wages on the rise, inflation could accelerate in the coming months due to the increase in the price of goods and services as a result of the import tariffs... [T]his may further boost expectations over rising price levels and in turn tightening of monetary policy from the Federal Reserve, which already looks set to hike interest rates two more times in 2018,�� Razaqzada said.

See: MarketWatch��s Economic Calendar

The euro EURUSD, +0.0086% �traded at $1.1656 compared to $1.1673 late in New York trading Wednesday.

The European Commission on Thursday cut its forecasts for the euro-zone��s economic growth this year, pointing to trade tensions with the U.S. and rising oil prices which push up inflation risks in the bloc.

The group now estimates that the 19-country euro zone will grow by 2.1% this year, lower than the 2.3% gross domestic product increase it had forecast in its previous estimates released in May, and further below the 2.4% growth recorded last year. In 2019 the bloc��s growth should further slow to 2%, they believe, unchanged from the previous forecast.

The euro had already turned more defensive, against the dollar in particular, on Wednesday after a report by Reuters suggested that policy makers at the European Central Bank are mixed about the timing of a possible rate-hike next year.

Top 5 Heal Care Stocks To Watch Right Now

tags:ALL,BA,BBW,GLPI,HBAN, Millennial men don't mind risky investments like Bitcoin, or boosting their money knowledge with the help of the financial media. But their female peers are wary of risk, leery of the unregulated world of cryptocurrencies and more apt to gain financial knowledge from family members and employers.����

Those�differing approaches to personal finance were highlighted in PNC�Investments' 2018�Millennials & Investing Survey, obtained exclusively by USA TODAY

The distinct mindsets about money, the survey says, likely date back to the Millennials' childhoods. When they were kids growing up, the "financial upbringing" boys and girls received from mom and dad had slightly different focuses. Females received a more conservative message, one emphasizing�"saving" rather than "investing."

Top 5 Heal Care Stocks To Watch Right Now: Allstate Corporation (ALL)

Advisors' Opinion:

• [By Shane Hupp]

  Allion (CURRENCY:ALL) traded up 4.4% against the US dollar during the 24 hour period ending at 8:00 AM Eastern on May 29th. One Allion coin can currently be purchased for $0.0143 or 0.00000193 BTC on popular exchanges including YoBit, Cryptopia and CoinExchange. Allion has a total market cap of $88,618.00 and $1,993.00 worth of Allion was traded on exchanges in the last 24 hours. During the last week, Allion has traded down 4.3% against the US dollar.

• [By Lee Jackson]

  Insurance companies tend to do well as rates rise, and this sector giant may be an outstanding pick for investors. Allstate Corp. (NYSE: ALL) is the largest publicly traded personal lines insurance company, with about 12% of the personal lines market (one in eight households). Allstate is primarily a direct writer. Besides a full array of personal lines P/C products (preferred, standard and nonstandard auto insurance, and homeowners’ insurance), the company also offers life insurance and annuity products.

• [By Shane Hupp]

  Principal Financial Group Inc. cut its position in Allstate (NYSE:ALL) by 7.4% in the 1st quarter, HoldingsChannel.com reports. The firm owned 2,075,644 shares of the insurance provider’s stock after selling 165,995 shares during the quarter. Principal Financial Group Inc.’s holdings in Allstate were worth $196,771,000 as of its most recent SEC filing.

• [By Stephan Byrd]

  Guggenheim Capital LLC grew its position in shares of Allstate Corp (NYSE:ALL) by 4.4% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 530,877 shares of the insurance provider’s stock after purchasing an additional 22,475 shares during the period. Guggenheim Capital LLC’s holdings in Allstate were worth $50,327,000 as of its most recent SEC filing.

Top 5 Heal Care Stocks To Watch Right Now: Boeing Company (BA)

Advisors' Opinion:

• [By Paul Ausick]

  The Boeing Co. (NYSE: BA) traded down 2.79% at $328.08. The stock’s 52-week range is $175.47 to $371.60. Volume was about 40% below the daily average of around 6.4 million. The company had no specific news Friday.

• [By Lou Whiteman]

  Boeing (NYSE:BA) is continuing its push into areas traditionally dominated by its supply base. Though the company's latest move is relatively small in terms of revenue, it seems likely to further enflame tensions, and lead to even more scrambling, between the aerospace giant and some of its key suppliers.

• [By Paul Ausick]

  The Dow stock posting the largest daily percentage gain ahead of the close Friday was The Boeing Co. (NYSE: BA) which traded up 3.49% at $363.49 in a 52-week range of $182.52 to $371.60. Volume was just above the daily average of around 5.16 million shares. The company had no specific news, but an easing of tensions with China helps this country’s largest exporter.

• [By Paul Ausick]

  The second-best performer among the Dow Jones industrials so far this year is Microsoft Corp. (NASDAQ: MSFT), which is up 15.28%. That is followed by Visa Inc. (NYSE: V), up 18.3%, UnitedHealthGroup Inc. (NYSE: UNH), up 13.7%, and Boeing Co. (NYSE: BA), up 13.5%. Of the 30 Dow stocks, only 11 have managed to post a gain to date in 2018.

• [By Paul Ausick]

  Following a one-week absence, The Boeing Co. (NYSE: BA) has returned as the top-performing stock among the Dow 30 last week. Unlike its performance in 2017 when it grabbed the top ranking early and held it for most of the year, Boeing has bounced into and out of the top spot this year. The company’s shares added about 3.6% in what was a good week for the index itself. For the year to date, Boeing shares have gained 25.3%.

Top 5 Heal Care Stocks To Watch Right Now: Build-A-Bear Workshop, Inc.(BBW)

Advisors' Opinion:

• [By Lisa Levin] Companies Reporting Before The Bell Dollar Tree, Inc. (NASDAQ: DLTR) is expected to report quarterly earnings at $1.23 per share on revenue of $5.56 billion. Express, Inc. (NYSE: EXPR) is projected to report quarterly loss at $0.02 per share on revenue of $466.25 million. Dollar General Corporation (NYSE: DG) is estimated to report quarterly earnings at $1.4 per share on revenue of $6.20 billion. Tech Data Corporation (NASDAQ: TECD) is expected to report quarterly earnings at $1.46 per share on revenue of $8.13 billion. Burlington Stores, Inc. (NYSE: BURL) is estimated to report quarterly earnings at $1.09 per share on revenue of $1.49 billion. Ciena Corporation (NYSE: CIEN) is projected to report quarterly earnings at $0.3 per share on revenue of $726.56 million. American Eagle Outfitters, Inc. (NYSE: AEO) is expected to report quarterly earnings at $0.22 per share on revenue of $806.17 million. Titan Machinery Inc. (NASDAQ: TITN) is estimated to report quarterly loss at $0.08 per share on revenue of $276.27 bmillion. Donaldson Company, Inc. (NYSE: DCI) is projected to post quarterly earnings at $0.52 per share on revenue of $682.68 million. Ship Finance International Limited (NYSE: SFL) is expected to report quarterly earnings at $0.21 per share on revenue of $92.08 million. Perry Ellis International, Inc. (NASDAQ: PERY) is projected to report quarterly earnings at $0.67 per share on revenue of $232.30 million. Kirkland's, Inc. (NASDAQ: KIRK) is estimated to report quarterly loss at $0.09 per share on revenue of $140.83 million. Build-A-Bear Workshop, Inc. (NYSE: BBW) is expected to report quarterly earnings at $0.18 per share on revenue of $90.20 million. J.Jill, Inc. (NYSE: JILL) is projected to report quarterly earnings at $0.19 per share on revenue of $160.50 million. Christopher & Banks Corporation (NYSE: CBK) is expected to report quarterly loss at $0.08 per share on revenue of $89.35 million.
• [By Joseph Griffin]

  News coverage about Build-A-Bear Workshop (NYSE:BBW) has been trending somewhat negative on Thursday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Build-A-Bear Workshop earned a media sentiment score of -0.07 on Accern’s scale. Accern also assigned media stories about the specialty retailer an impact score of 43.9525750448852 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

• [By Lisa Levin]

    

  Clearside Biomedical, Inc. (NASDAQ: CLSD) shares declined 32.19 percent to close at $9.86 on Thursday. Clearside Biomedical disclosed that its Phase 2 trial of CLS-TA met primary and secondary endpoints met in 6-month trial. scPharmaceuticals Inc. (NASDAQ: SCPH) shares dipped 30.1 percent to close at $9.94 on Thursday after the FDA identified deficiencies in the company’s New Drug Application for FUROSCIX. However, the FDA letter did not specify deficiencies identified and notification does not reflect final decision on information under review. Euroseas Ltd. (NASDAQ: ESEA) fell 24.08 percent to close at $1.86. Euroseas announced completion of the spin-off of its drybulk fleet into EuroDry Ltd. Golar LNG Limited (NASDAQ: GLNG) fell 25.09 percent to close at $25.98 following Q1 results. Oragenics, Inc. (NASDAQ: OGEN) shares dropped 25 percent to close at $1.50 on Thursday. Guess', Inc. (NYSE: GES) dropped 19.44 percent to close at $19.60 following Q1 results. Cantel Medical Corp. (NYSE: CMD) dropped 15.94 percent to close at $109.09 on Thursday following FQ3 results. Fusion Connect, Inc. (NASDAQ: FSNN) shares fell 15.55 percent to close at $3.91. Build-A-Bear Workshop, Inc. (NYSE: BBW) dropped 14.44 percent to close at $8.00 after reporting Q1 results. Dollar Tree, Inc. (NASDAQ: DLTR) shares declined 14.28 percent to close at $82.59 after the company reported weaker-than-expected earnings for its first quarter and lowered its FY2018 earnings guidance. Titan Machinery Inc. (NASDAQ: TITN) dropped 13.94 percent to close at $18.09 after reporting Q1 results. Co-Diagnostics, Inc. (NASDAQ: CODX) declined 13.17 percent to close at $2.90 after declining 5.65 percent on Wednesday. Concordia International Corp. (NASDAQ: CXRX) fell 12.89 percent to close at $0.2440 after the company announced that it would be delisted from the Nasdaq. Sears Holdings Corporation (NASDAQ: SHLD) slipped 12.46 percent

Top 5 Heal Care Stocks To Watch Right Now: Gaming and Leisure Properties, Inc.(GLPI)

Advisors' Opinion:

• [By Lisa Levin]

  Check out these big penny stock gainers and losers

  Losers Teradyne, Inc. (NYSE: TER) fell 10.8 percent to $37.02 in pre-market trading after the company issued downbeat Q2 guidance. Edwards Lifesciences Corporation (NYSE: EW) fell 9.2 percent to $122.29 in pre-market trading. Edwards Lifesciences reported better-than-expected results for its first quarter, but issued weak earnings guidance for the second quarter. New Gold Inc. (NYSE: NGD) fell 8.8 percent to $2.30 in pre-market trading after rising 4.13 percent on Tuesday. Gold Fields Limited (ADR) (NYSE: GFI) fell 8.6 percent to $3.61 in pre-market trading. Natus Medical Incorporated (NASDAQ: BABY) fell 8.2 percent to $32.95 in pre-market trading after the company issued weak forecast for the second quarter. Atossa Genetics Inc. (NASDAQ: ATOS) shares fell 7.9 percent to $3.50 in pre-market trading after climbing 27.09 percent on Tuesday. Bright Scholar Education Holdings Limited (NYSE: BEDU) shares fell 6.7 percent to $13.58 in pre-market trading after reporting Q1 results. Sangamo Therapeutics Inc (NASDAQ: SGMO) fell 5.9 percent to $16.75 in pre-market trading following announcement of a $200 million common stock offering. Foresight Autonomous Holdings Ltd (NASDAQ: FRSX) shares fell 5.7 percent to $3.29 in pre-market trading after declining 3.32 percent on Tuesday. Euronav NV (NYSE: EURN) fell 4.8 percent to $8.40 in pre-market trading. Limelight Networks, Inc. (NASDAQ: LLNW) shares fell 4.3 percent to $4.69 in pre-market trading. Gaming and Leisure Properties Inc (NASDAQ: GLPI) shares fell 4.1 percent to $32.92 in pre-market trading after the company issued downbeat quarterly results and reported the retirement of CFO William Clifford
• [By Ethan Ryder]

  News articles about Gaming and Leisure Properties (NASDAQ:GLPI) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Gaming and Leisure Properties earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned media headlines about the real estate investment trust an impact score of 46.8663126119297 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

• [By Jason Hall, Neha Chamaria, and Rich Duprey]

  Owning stocks that pay a dividend can make it much easier to hold on to them, particularly if they have the ability to steadily increase the payout and solid prospects to grow the business. To help find the best long-term dividend stocks out there, we asked three of our Motley Fool investors for a little help. They came back with�Gaming and Leisure Properties Inc�(NASDAQ:GLPI),�AES Corp�(NYSE:AES), and�Caretrust REIT Inc�(NASDAQ:CTRE).�

Top 5 Heal Care Stocks To Watch Right Now: Huntington Bancshares Incorporated(HBAN)

Advisors' Opinion:

• [By Max Byerly]

  Envestnet Asset Management Inc. lifted its stake in shares of Huntington Bancshares (NASDAQ:HBAN) by 33.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 196,941 shares of the bank’s stock after buying an additional 49,653 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Huntington Bancshares were worth $2,972,000 as of its most recent filing with the Securities and Exchange Commission.

• [By Stephan Byrd]

  BidaskClub upgraded shares of Huntington Bancshares (NASDAQ:HBAN) from a hold rating to a buy rating in a report published on Wednesday morning.

  HBAN has been the topic of a number of other research reports. Zacks Investment Research lowered Huntington Bancshares from a buy rating to a hold rating in a research report on Thursday, April 5th. Nomura reduced their price target on Huntington Bancshares from $18.00 to $17.00 and set a buy rating on the stock in a research report on Wednesday, April 25th. Susquehanna Bancshares set a $17.00 price target on Huntington Bancshares and gave the company a hold rating in a research report on Tuesday, April 24th. UBS Group began coverage on Huntington Bancshares in a research report on Wednesday, March 21st. They issued a buy rating and a $20.00 price target on the stock. Finally, Hilliard Lyons upgraded Huntington Bancshares from a neutral rating to a buy rating and set a $17.00 price target on the stock in a research report on Friday, February 9th. Ten analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $16.98.

• [By Ethan Ryder]

  Here are some of the news stories that may have effected Accern Sentiment’s analysis:

  Get Huntington Bancshares alerts: Yesterday Trading Recap Huntington Bancshares Incorporated (HBAN) Stock Price trades 4.85% (nasdaqchronicle.com) Huntington Bank Reports Increased Loan Production In SBA Fiscal Q2 2018 (finance.yahoo.com) Huntington Bancshares Incorporated (NasdaqGS:HBAN) Boasting an ROIC Quality Score of -5.502819 (colbypost.com) Investor’s Alert (Earnings Per Share) �� Huntington Bancshares Incorporated (NASDAQ:HBAN) (thestockgem.com) $1.13 Billion in Sales Expected for Huntington Bancshares (HBAN) This Quarter (americanbankingnews.com)

  Huntington Bancshares opened at $15.69 on Friday, according to MarketBeat. The firm has a market cap of $17.14 billion, a price-to-earnings ratio of 16.01, a P/E/G ratio of 1.08 and a beta of 1.32. The company has a current ratio of 0.88, a quick ratio of 0.88 and a debt-to-equity ratio of 0.85. Huntington Bancshares has a 52-week low of $12.14 and a 52-week high of $16.60.

• [By Max Byerly]

  Here are some of the headlines that may have impacted Accern Sentiment’s rankings:

  Get Huntington Bancshares alerts: Active Mover: Huntington Bancshares Incorporated (NASDAQ: HBAN) (alphabetastock.com) P/E Ratio under Consideration �� Huntington Bancshares Incorporated (NASDAQ: HBAN) (stocksmarketcap.com) Stocks You Can’t Afford to Pass Up: Huntington Bancshares Incorporated (NASDAQ:HBAN), Under Armour, Inc. (NYSE … (journalfinance.net) Is this stock is Oversold? Huntington Bancshares Incorporated (HBAN) (stockquote.review) Huntington Bancshares Incorporated (NasdaqGS:HBAN) & Eldorado Resorts, Inc. (NasdaqGS:ERI) Valuation at a Glance (parkcitycaller.com)

  Several equities research analysts have issued reports on the company. BidaskClub lowered Huntington Bancshares from a “buy” rating to a “hold” rating in a research note on Wednesday. JPMorgan Chase lifted their price objective on Huntington Bancshares from $16.00 to $17.00 and gave the stock a “neutral” rating in a report on Thursday, January 25th. Zacks Investment Research downgraded Huntington Bancshares from a “buy” rating to a “hold” rating in a report on Thursday, April 5th. BMO Capital Markets reiterated a “hold” rating and issued a $18.00 price objective on shares of Huntington Bancshares in a report on Wednesday, January 24th. Finally, Keefe, Bruyette & Woods reiterated a “hold” rating and issued a $16.75 price objective on shares of Huntington Bancshares in a report on Wednesday, January 24th. Ten investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $16.98.

• [By Lisa Levin] Companies Reporting Before The Bell United Technologies Corporation (NYSE: UTX) is estimated to report quarterly earnings at $1.51 per share on revenue of $14.62 billion. The Coca-Cola Company (NYSE: KO) is expected to report quarterly earnings at $0.46 per share on revenue of $7.31 billion. Caterpillar Inc. (NYSE: CAT) is projected to report quarterly earnings at $2.07 per share on revenue of $11.93 billion. Verizon Communications Inc. (NYSE: VZ) is expected to report quarterly earnings at $1.11 per share on revenue of $31.22 billion. Lockheed Martin Corporation (NYSE: LMT) is estimated to report quarterly earnings at $3.42 per share on revenue of $11.28 billion. The Sherwin-Williams Company (NYSE: SHW) is projected to report quarterly earnings at $3.15 per share on revenue of $3.94 billion. Biogen Inc. (NASDAQ: BIIB) is expected to report quarterly earnings at $5.92 per share on revenue of $3.15 billion. 3M Company (NYSE: MMM) is estimated to report quarterly earnings at $2.52 per share on revenue of $8.26 billion. JetBlue Airways Corporation (NASDAQ: JBLU) is projected to report quarterly earnings at $0.2 per share on revenue of $1.75 billion. Eli Lilly and Company (NYSE: LLY) is expected to report quarterly earnings at $1.13 per share on revenue of $5.49 billion. Harley-Davidson, Inc. (NYSE: HOG) is estimated to report quarterly earnings at $0.88 per share on revenue of $1.25 billion. Corning Incorporated (NYSE: GLW) is expected to report quarterly earnings at $0.3 per share on revenue of $2.50 billion. Centene Corporation (NYSE: CNC) is projected to report quarterly earnings at $1.88 per share on revenue of $13.28 billion. The Travelers Companies, Inc. (NYSE: TRV) is estimated to report quarterly earnings at $2.77 per share on revenue of $6.75 billion. Wipro Limited (NYSE: WIT) is expected to report quarterly earnings at $0.07 per share on revenue of $2.16 billion. PACCAR Inc (NASDAQ: PCAR) is projected to
• [By Max Byerly]

  Public Employees Retirement Association of Colorado lessened its stake in shares of Huntington Bancshares (NASDAQ:HBAN) by 4.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 197,768 shares of the bank’s stock after selling 10,068 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Huntington Bancshares were worth $2,986,000 at the end of the most recent reporting period.

Cash In on the Fintech Revolution with This Payments Stock

Michael A. Robinson

Alex Kutsishin is one of the reasons why I'm so excited about the rapidly emerging field of finance technology.

Called "fintech" for short, this is an area that will touch virtually every aspect of the $70 trillion global economy over the next several years.

Here's what I mean…

By definition, every single transaction involves some sort of payment. Increasingly, those payments are moving to digital systems – and eventually virtually all of them will get there.

And that means every aspect of finance today – from hedge funds to bond management to buying a pack of gum at your corner market – is ripe for tech disruption.

That innovation is coming from savvy entrepreneurs like Alex Kutsishin, the CEO and founder of fintech startup Sales Boomerang, which focuses on helping banks plug billions in home loan leaks.

I recently spent a couple hours talking with Kutsishin on a flight home from Money Map Press headquarters in Baltimore to Silicon Valley.

I had intended to tune out my fellow passengers and listen to some music while catching up on work. But after introducing ourselves, Kutsishin couldn't help but explain further exactly what he did.

I found his spiel so fascinating – and potentially lucrative – that I put my headphones down… leaned in… and listened.

Today I'll introduce Kutsishin and Sales Boomerang to you folks.

Unfortunately, his company is privately held and you can't invest in it… yet.

But I have found a great way you can play the red-hot fintech trend.

This stock is going to blow the doors off Wall Street – and it could put a bunch of money in your pocket…

Tackling the Credit Score Disconnect

As my longtime readers can attest, my interest in fintech goes back 30 years. In the late 1980s, I worked as the San Francisco bureau chief for American Banker, a trade journal known as the "bible of the industry."

And I was there just as bankers began adopting more sophisticated computer technology. Of course, by today's standards those tech platforms would seem like tools from the Stone Age.

But here's the thing – I saw firsthand what can happen when fintech is done poorly. I broke a series of stories about a mismanaged computer network changeover at Bank of America, uncovering a $60 million mistake.

Those stories led to the dismissal of two executive vice presidents.

In other words, I know just how important good fintech is to the financial services industry – and why a great tech platform can be worth its weight in gold.

Free Book: The secrets in this book helped one Money Morning reader make a $185,253 profit in just eight days. Learn how to claim your copy here…

That's where Kutsishin and Sales Boomerang come in.

Turns out, he's targeting a big financial drain among lenders.

See, every lender in the nation uses credit scores to determine if a customer qualifies for a loan. Not surprisingly, many customers have credit blemishes that could be cleaned up in a year or less. The problem is figuring out when those customers cross that threshold – when they become credit-worthy.

The disconnect, and Kutsishin's hook in the home-loan market, is that most banks today have no way of tracking those clients even if they're using customer relationship management (CRM) software.

It's sort of like having bank managers walk down the street and leaving $100 bills on the sidewalk.

Putting Profits "on Steroids"

Enter Sales Boomerang and its sophisticated, cloud-based tracking system that alerts creditors the moment someone the startup is tracking qualifies for a loan.

During our flight, Kutsishin ran some numbers to show me how powerful Sales Boomerang's platform can be.

If a lender receives just 1,000 requests a month for an average mortgage of $250,000, Sales Boomerang could deliver $90 billion in extra loan volume per year. And that's assuming a mere 5% conversion rate – and at just one lender.

"This is taking the lender's return on investment and putting it on steroids," Kutsishin told me. "When we show this to potential clients, they're just blown away."

No wonder lenders like AmCap Mortgage, Centennial Lending Group, and USA Mortgage have signed on as Sales Boomerang clients.

But there's more going on in fintech than just Kutsishin's success.

A lot more.

In fact, the whole sector is really heating up.

According to data from the venture capital trackers at Crunchbase, since 2016, fintech startups have raised more than $15.6 billion. And the money is coming in quick. Crunchbase says the sector saw 136 VC deals in the first quarter alone.

We're also seeing established firms grabbing startups and folding them into their operations. In roughly the last six months, there were at least 30 fintech mergers, according to online tracker Index by TNW.

That's why I think savvy tech investors ought to take a run at this payments stock…

Join the conversation. Click here to jump to comments…

Michael A. Robinson

About the Author

Browse Michael's articles | View Michael's research services

Michael A. Robinson is one of the top financial analysts working today. His book "Overdrawn: The Bailout of American Savings" was a prescient look at the anatomy of the nation's S&L crisis, long before the word "bailout" became part of our daily lexicon. He's a Pulitzer Prize-nominated writer and reporter, lauded by the Columbia Journalism Review for his aggressive style. His 30-year track record as a leading tech analyst has garnered him rave reviews, too. Today he is the editor of the monthly tech investing newsletter Nova-X Report as well as Radical Technology Profits, where he covers truly radical technologies �� ones that have the power to sweep across the globe and change the very fabric of our lives �� and profit opportunities they give rise to. He also explores "what's next" in the tech investing world at Strategic Tech Investor.

… Read full bio

This Is an Unprecedented Opportunity for Investing in Marijuana Stocks

We're just three months away from one of the most historic moments the world will ever see: Marijuana in Canada will be completely legal by October.

We already know there's a market for marijuana up north.

We even know how big it is.

In 2016, it was $5.13 billion…

And Deloitte says it's going to be as high as $22.6 billion over the next couple of years.

The only problem was it was all illegal until June 19.

The money wasn't going to legitimate businesses. It was going to the black market.

The June 19 vote by Canadian officials to legalize all cannabis use was like flipping a light switch. Those billions of dollars are up for grabs.

Now, Canadian marijuana is going to the fastest-growing industry on earth for the next five years.

Drop Everything: Canada just became the first major economy to legalize marijuana nationwide, giving investors a once-in-a-lifetime chance to potentially make millions of dollars from Canadian marijuana companies. Learn more…

It's going to beat big pharmaceuticals.

It's going to grow faster than tech companies like Apple Inc. (Nasdaq: AAPL), Uber, or Netflix Inc. (Nasdaq: NFLX).

It's even going to beat cryptocurrencies.

Let us tell you why.

In 2017,�cryptocurrencies had their best year ever,�with the market growing by 3,086%.

That's 164 times faster than the S&P 500.

And yet, the Canadian marijuana industry has the potential to grow much, much faster than that.

Experts predict the legal marijuana market could grow by nearly 9,000% in Canada alone�– far faster than anything else on the planet.

But it's only the tip of the iceberg. Because global sales could bump that as high as 44,400% over the next few years alone if Canada captures the entire illegal marijuana market.

That's 2,336 times faster than the S&P 500 and 14 times faster than cryptocurrency growth last year.

Just imagine what that kind of growth could do to your money…

It's mind-boggling.

This is an honest chance for regular, everyday people to become millionaires in the next few months…

Follow�Money Morning�on�Twitter,�Facebook, and�LinkedIn.

Join the conversation. Click here to jump to comments…

Comparing Brookfield Renewable Partners (BEP) and NRG Yield Inc Class C (NYLD)

Brookfield Renewable Partners (NYSE: BEP) and NRG Yield Inc Class C (NYSE:NYLD) are both mid-cap utilities companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings and dividends.

Risk and Volatility

Get Brookfield Renewable Partners alerts:

Brookfield Renewable Partners has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500. Comparatively, NRG Yield Inc Class C has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500.

Dividends

Brookfield Renewable Partners pays an annual dividend of $1.96 per share and has a dividend yield of 6.4%. NRG Yield Inc Class C pays an annual dividend of $1.24 per share and has a dividend yield of 7.0%. Brookfield Renewable Partners pays out -1,088.9% of its earnings in the form of a dividend. NRG Yield Inc Class C pays out 153.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Brookfield Renewable Partners has raised its dividend for 4 consecutive years.

Profitability

This table compares Brookfield Renewable Partners and NRG Yield Inc Class C’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Brookfield Renewable Partners	3.79%	0.80%	0.36%
NRG Yield Inc Class C	0.30%	4.10%	1.09%

Institutional & Insider Ownership

54.2% of Brookfield Renewable Partners shares are held by institutional investors. Comparatively, 29.1% of NRG Yield Inc Class C shares are held by institutional investors. 0.2% of NRG Yield Inc Class C shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Brookfield Renewable Partners and NRG Yield Inc Class C’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brookfield Renewable Partners	$2.63 billion	2.10	-$4.00 million	($0.18)	-169.89
NRG Yield Inc Class C	$1.01 billion	3.23	-$8.00 million	$0.81	21.73

Brookfield Renewable Partners has higher revenue and earnings than NRG Yield Inc Class C. Brookfield Renewable Partners is trading at a lower price-to-earnings ratio than NRG Yield Inc Class C, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Brookfield Renewable Partners and NRG Yield Inc Class C, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brookfield Renewable Partners	0	9	3	0	2.25
NRG Yield Inc Class C	0	4	2	0	2.33

Brookfield Renewable Partners presently has a consensus target price of $36.11, indicating a potential upside of 18.09%. NRG Yield Inc Class C has a consensus target price of $18.00, indicating a potential upside of 2.27%. Given Brookfield Renewable Partners’ higher probable upside, analysts clearly believe Brookfield Renewable Partners is more favorable than NRG Yield Inc Class C.

Summary

NRG Yield Inc Class C beats Brookfield Renewable Partners on 9 of the 17 factors compared between the two stocks.

Brookfield Renewable Partners Company Profile

Brookfield Renewable Partners L.P. owns a portfolio of renewable power generating facilities in the North America, Colombia, Brazil, Europe, and internationally. The company operates through Hydroelectric; Wind; and Solar, Storage, and others segments. It operates 840 generation facilities using hydro, solar, wind, biomass, and other renewable technologies. Brookfield Renewable Partners Limited operates as the general partner of Brookfield Renewable Partners L.P. The company was formerly known as Brookfield Renewable Energy Partners L.P. and changed its name to Brookfield Renewable Partners L.P. in May 2016. The company was founded in 1999 and is based in Hamilton, Bermuda. Brookfield Renewable Partners L.P. is a subsidiary of Brookfield Renewable Partners Limited.

NRG Yield Inc Class C Company Profile

NRG Yield, Inc., through its subsidiaries, acquires, owns, and operates contracted renewable and conventional generation, and thermal infrastructure assets in the United States. As of December 31, 2017, it had contracted renewable and conventional generation portfolio of 5,118 net megawatt (MW). The company also owns thermal infrastructure assets with an aggregate steam and chilled water capacity of 1,319 net MW thermal equivalents, and electric generation capacity of 123 net MW. Its thermal infrastructure assets provide steam, hot water and/or chilled water, and electricity to commercial businesses, universities, hospitals, and governmental units. The company was founded in 2012 and is based in Princeton, New Jersey. NRG Yield, Inc. is a subsidiary of NRG Energy, Inc.

Piper Jaffray Companies Analysts Lower Earnings Estimates for Asante Solutions Inc (PUMP)

Asante Solutions Inc (NASDAQ:PUMP) – Equities researchers at Piper Jaffray Companies dropped their Q3 2018 earnings per share estimates for shares of Asante Solutions in a research report issued to clients and investors on Sunday, July 1st. Piper Jaffray Companies analyst J. Daniel now anticipates that the company will post earnings per share of $0.48 for the quarter, down from their previous estimate of $0.50. Piper Jaffray Companies currently has a “Buy” rating and a $19.00 target price on the stock. Piper Jaffray Companies also issued estimates for Asante Solutions’ FY2018 earnings at $1.83 EPS, Q1 2019 earnings at $0.40 EPS, Q2 2019 earnings at $0.39 EPS, Q3 2019 earnings at $0.41 EPS and FY2019 earnings at $1.68 EPS.

Get Asante Solutions alerts:

PUMP has been the topic of a number of other research reports. Royal Bank of Canada set a $20.00 target price on Asante Solutions and gave the company a “buy” rating in a report on Wednesday, March 28th. Macquarie assumed coverage on Asante Solutions in a report on Friday, June 8th. They issued a “neutral” rating and a $17.00 target price on the stock. Tudor Pickering downgraded Asante Solutions from a “buy” rating to a “hold” rating in a report on Friday, June 8th. Cowen reaffirmed a “market perform” rating and issued a $14.00 target price (up previously from $13.00) on shares of Asante Solutions in a report on Thursday, May 10th. Finally, Jefferies Financial Group set a $21.00 target price on Asante Solutions and gave the company a “buy” rating in a report on Tuesday, March 27th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $21.73.

Shares of PUMP stock opened at $15.63 on Wednesday. Asante Solutions has a fifty-two week low of $10.84 and a fifty-two week high of $22.88.

Asante Solutions (NASDAQ:PUMP) last issued its earnings results on Tuesday, May 8th. The company reported $0.42 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.38 by $0.04. The business had revenue of $385.20 million during the quarter, compared to analyst estimates of $375.75 million. The company’s revenue for the quarter was up 124.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.43) EPS.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Hancock Holding Co. lifted its stake in shares of Asante Solutions by 1.2% in the 1st quarter. Hancock Holding Co. now owns 520,980 shares of the company’s stock valued at $8,279,000 after acquiring an additional 6,005 shares during the last quarter. New York State Common Retirement Fund lifted its stake in shares of Asante Solutions by 22.3% in the 1st quarter. New York State Common Retirement Fund now owns 62,000 shares of the company’s stock valued at $985,000 after acquiring an additional 11,300 shares during the last quarter. GW&K Investment Management LLC bought a new position in shares of Asante Solutions in the 1st quarter valued at $224,000. Metropolitan Life Insurance Co. NY bought a new position in shares of Asante Solutions in the 4th quarter valued at $378,000. Finally, American International Group Inc. lifted its stake in shares of Asante Solutions by 126.9% in the 4th quarter. American International Group Inc. now owns 38,425 shares of the company’s stock valued at $775,000 after acquiring an additional 21,491 shares during the last quarter.

In other news, Director Pryor Blackwell purchased 13,404 shares of the company’s stock in a transaction dated Thursday, June 7th. The stock was bought at an average cost of $15.36 per share, for a total transaction of $205,885.44. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

About Asante Solutions

Asante Solutions, Inc is a medical device company. The Company is a manufacturer of Asante Snap Insulin Pump System (Snap system), which is a pump featuring a modular design with pre-filled insulin cartridges and disposable pump bodies, utilized in combination with a controller. The Snap system comprises four components: the Snap system controller, a disposable pump body, disposable pre-filled insulin cartridges and disposable infusion sets.

Hot Low Price Stocks To Buy Right Now

tags:AAON,LFC,PER, In what would be a blow to American aerospace giant Boeing, Delta Air Lines is set to order around 100 jetliners from European rival Airbus, according to two people familiar with the deal.

Atlanta-based Delta will announce a deal later Wednesday for the Airbus A321neo, the sources said. The agreement with Airbus maker will be accompanied by a planned purchase of Pratt & Whitney engines, they added.

Spokespeople for Delta (DAL)and Airbus declined to comment. Boeing (BA) said it had no comment. Delta's board of directors is expected to meet Wednesday to vote on the Airbus purchase, the sources said.

Delta had been talking to Boeing about buying around 100 of its 737 Max 10 airliners, a person familiar with the matter said.

The move comes a day after Canada announced plans to ditch a deal with Boeing for new F/A-18 Super Hornets in favor of used fighters from Australia.

Boeing and Delta are embroiled in an ongoing trade dispute over the airline's purchase of the smaller Canadian Bombardier C Series. Boeing has accused Bombardier of selling the C Series to Delta at unfairly low prices, and the U.S. Commerce Department has recommended a preliminary 300% tariff on the import of the jets. Bombardier and the Canadian government deny any unfair trade practices.

Hot Low Price Stocks To Buy Right Now: AAON Inc.(AAON)

Advisors' Opinion:

• [By Stephan Byrd]

  Get a free copy of the Zacks research report on AAON (AAON)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Max Byerly]

  AAON (NASDAQ:AAON) – Equities researchers at DA Davidson cut their Q1 2018 earnings per share (EPS) estimates for shares of AAON in a report issued on Wednesday, April 11th. DA Davidson analyst B. Thielman now expects that the construction company will earn $0.24 per share for the quarter, down from their prior forecast of $0.25.

• [By Logan Wallace]

  California Public Employees Retirement System lowered its stake in shares of AAON, Inc. (NASDAQ:AAON) by 24.3% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 117,279 shares of the construction company’s stock after selling 37,675 shares during the period. California Public Employees Retirement System’s holdings in AAON were worth $4,574,000 as of its most recent filing with the SEC.

• [By Ethan Ryder]

  AAON (NASDAQ:AAON) reached a new 52-week high and low on Friday . The stock traded as low as $29.05 and last traded at $30.50, with a volume of 203355 shares trading hands. The stock had previously closed at $31.65.

Hot Low Price Stocks To Buy Right Now: China Life Insurance Company Limited(LFC)

Advisors' Opinion:

• [By Logan Wallace]

  China Life Insurance Co Ltd (NYSE:LFC) has received a consensus recommendation of “Hold” from the thirteen research firms that are presently covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $13.85.

• [By Logan Wallace]

  Here are some of the media stories that may have impacted Accern Sentiment’s rankings:

  Get China Life Insurance alerts: Critical Comparison: AXA (AXAHY) & China Life Insurance (LFC) (americanbankingnews.com) Zacks Value Investor Highlights: Apple, Amazon, Alphabet, China Life Insurance and Jacobs Engineering (finance.yahoo.com) China Life Insurance (LFC) Rating Lowered to Sell at Goldman Sachs (americanbankingnews.com) Head to Head Comparison: China Life Insurance (LFC) & The Competition (americanbankingnews.com) Contrasting China Life Insurance (LFC) and Its Competitors (americanbankingnews.com)

  China Life Insurance traded up $0.23, hitting $14.32, during midday trading on Friday, MarketBeat Ratings reports. The company’s stock had a trading volume of 454,100 shares, compared to its average volume of 692,520. The company has a current ratio of 8.45, a quick ratio of 8.45 and a debt-to-equity ratio of 0.05. China Life Insurance has a 12 month low of $13.48 and a 12 month high of $17.85. The stock has a market cap of $81.12 billion, a PE ratio of 15.40, a price-to-earnings-growth ratio of 0.49 and a beta of 1.57.

Hot Low Price Stocks To Buy Right Now: SandRidge Permian Trust(PER)

Advisors' Opinion:

• [By Max Byerly]

  Media coverage about SandRidge Permian Trust (NYSE:PER) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. SandRidge Permian Trust earned a coverage optimism score of 0.04 on Accern’s scale. Accern also gave news headlines about the oil and gas producer an impact score of 46.3601951962152 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.